Everything we've seen

1. ?Sep 14, 10:20 AMdecisionconsidered

   Agent 7 — Day Trader — decide: skip

   DXCM is up 1.56% today, a modest but real move suggesting some buying interest. No news is available to explain the move, which is common — flow-driven moves can persist. The macro context (T10Y2Y at 0.33, 1.9σ below trend) reflects a mildly flattening yield curve, which tends to be neutral-to-slightly-negative for growth/medtech names like DXCM, as it signals subdued growth expectations. However, this is not a strong headwind for a single-session intraday continuation. With 325 minutes remaining (roughly 5+ hours until close), there is ample time for the move to extend, which is a positive factor. The move magnitude at 1.56% is below the 2-5% 'high conviction' threshold, so momentum evidence is moderate rather than strong. No reversal signals or fade pattern are evident from the data provided. On balance, the setup is a mild continuation lean — no strong catalyst but also no reason to expect fade, with plenty of session time remaining. Assigning a modest continuation probability just above the trigger threshold.

2. !Sep 14, 10:20 AMsignalseverity 0.02

   Agent 7 — Day Trader — day_trade_skipped

   DXCM is up 1.56% today, a modest but real move suggesting some buying interest. No news is available to explain the move, which is common — flow-driven moves can persist. The macro context (T10Y2Y at 0.33, 1.9σ below trend) reflects a mildly flattening yield curve, which tends to be neutral-to-slightly-negative for growth/medtech names like DXCM, as it signals subdued growth expectations. However, this is not a strong headwind for a single-session intraday continuation. With 325 minutes remaining (roughly 5+ hours until close), there is ample time for the move to extend, which is a positive factor. The move magnitude at 1.56% is below the 2-5% 'high conviction' threshold, so momentum evidence is moderate rather than strong. No reversal signals or fade pattern are evident from the data provided. On balance, the setup is a mild continuation lean — no strong catalyst but also no reason to expect fade, with plenty of session time remaining. Assigning a modest continuation probability just above the trigger threshold.

3. ?Sep 14, 7:01 AMdecisionconsidered

   Agent 5 — Dip Buyer (Evolving) — decide: skip

   DXCM is down 10.2% from its 30-day high with no evident fundamental deterioration in recent filings. However, the signal stack is net negative: the options flow shows unusually elevated put volume (P/C ratio 1.79, call z-score of -2.21 indicating below-average call activity), the 10Y yield at 4.83% is a structural headwind for a growth-sensitive medtech name, earnings are 47 days away (a headwind but not a hard veto), the Health Care sector is underperforming SPY meaningfully (-4.24pts over 30 days, which is a mild positive), and there is one insider sale. The broad market tone today is positive but the sector flow proxy is sharply negative (-$7M). Net signal score is approximately -1 to 0, not clearing the +2 bar needed for conviction.

4. !Sep 14, 7:01 AMsignalseverity 0.10

   Agent 5 — Dip Buyer (Evolving) — dip_skipped

   DXCM is down 10.2% from its 30-day high with no evident fundamental deterioration in recent filings. However, the signal stack is net negative: the options flow shows unusually elevated put volume (P/C ratio 1.79, call z-score of -2.21 indicating below-average call activity), the 10Y yield at 4.83% is a structural headwind for a growth-sensitive medtech name, earnings are 47 days away (a headwind but not a hard veto), the Health Care sector is underperforming SPY meaningfully (-4.24pts over 30 days, which is a mild positive), and there is one insider sale. The broad market tone today is positive but the sector flow proxy is sharply negative (-$7M). Net signal score is approximately -1 to 0, not clearing the +2 bar needed for conviction.

5. ?Sep 14, 7:00 AMdecisionconsidered

   Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

   DXCM is down 10.2% from its 30-day high with no clear fundamental impairment visible — no negative earnings revision, no guidance cut, and no company-specific bad news in recent filings or headlines. However, the options flow is notably bearish: P/C ratio of 1.79 with call volume deeply below normal (z=-2.21) and elevated put volume, suggesting informed participants are hedging or positioning for further downside. The sector context is also unfavorable — Health Care ranks 6th of 11 by 30-day relative strength, underperforming SPY by 4.24pts over 30 days, and today's sector flow proxy is heavily negative. Combined with a single insider sale (EVP) on the dip and elevated 10Y yields at 4.83% creating valuation headwinds for growth-oriented med-tech names, the risk/reward is not clearly asymmetric in favor of a large rebound.

6. !Sep 14, 7:00 AMsignalseverity 0.10

   Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

   DXCM is down 10.2% from its 30-day high with no clear fundamental impairment visible — no negative earnings revision, no guidance cut, and no company-specific bad news in recent filings or headlines. However, the options flow is notably bearish: P/C ratio of 1.79 with call volume deeply below normal (z=-2.21) and elevated put volume, suggesting informed participants are hedging or positioning for further downside. The sector context is also unfavorable — Health Care ranks 6th of 11 by 30-day relative strength, underperforming SPY by 4.24pts over 30 days, and today's sector flow proxy is heavily negative. Combined with a single insider sale (EVP) on the dip and elevated 10Y yields at 4.83% creating valuation headwinds for growth-oriented med-tech names, the risk/reward is not clearly asymmetric in favor of a large rebound.

7. ?Sep 11, 6:04 PMdecisionconsidered

   Agent 4 — Dip Buyer (Frozen) — decide: skip

   DXCM is down 10.3% from its 30-day high with no company-specific negative news headlines in the window and no meaningful metrics surfacing from the recent SEC filings to indicate fundamental deterioration. The 8-K filed on 2026-09-10 (the day before today) is notable but lacks disclosed metrics, suggesting it may be routine or immaterial. The primary headwind is macro: the 5-year forward inflation rate (T5YIFR) is running 1.8σ above its 24-month trend, pressuring rate-sensitive and growth-oriented names like DXCM. A moderate-to-fair rebound probability reflects the absence of company-specific bad news offset by a meaningful macro drag.

8. !Sep 11, 6:04 PMsignalseverity 0.10

   Agent 4 — Dip Buyer (Frozen) — dip_skipped

   DXCM is down 10.3% from its 30-day high with no company-specific negative news headlines in the window and no meaningful metrics surfacing from the recent SEC filings to indicate fundamental deterioration. The 8-K filed on 2026-09-10 (the day before today) is notable but lacks disclosed metrics, suggesting it may be routine or immaterial. The primary headwind is macro: the 5-year forward inflation rate (T5YIFR) is running 1.8σ above its 24-month trend, pressuring rate-sensitive and growth-oriented names like DXCM. A moderate-to-fair rebound probability reflects the absence of company-specific bad news offset by a meaningful macro drag.

9. ?Sep 11, 4:20 PMdecisionconsidered

   Agent 5 — Dip Buyer (Evolving) — decide: skip

   DXCM is down 10.2% from its 30-day high with no evident fundamental deterioration in recent filings. However, the signal stack is net negative: the options flow shows unusually elevated put volume (P/C ratio 1.79, call z-score of -2.21 indicating below-average call activity), the 10Y yield at 4.83% is a structural headwind for a growth-sensitive medtech name, earnings are 47 days away (a headwind but not a hard veto), the Health Care sector is underperforming SPY meaningfully (-4.24pts over 30 days, which is a mild positive), and there is one insider sale. The broad market tone today is positive but the sector flow proxy is sharply negative (-$7M). Net signal score is approximately -1 to 0, not clearing the +2 bar needed for conviction.

10. !Sep 11, 4:20 PMsignalseverity 0.10

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    DXCM is down 10.2% from its 30-day high with no evident fundamental deterioration in recent filings. However, the signal stack is net negative: the options flow shows unusually elevated put volume (P/C ratio 1.79, call z-score of -2.21 indicating below-average call activity), the 10Y yield at 4.83% is a structural headwind for a growth-sensitive medtech name, earnings are 47 days away (a headwind but not a hard veto), the Health Care sector is underperforming SPY meaningfully (-4.24pts over 30 days, which is a mild positive), and there is one insider sale. The broad market tone today is positive but the sector flow proxy is sharply negative (-$7M). Net signal score is approximately -1 to 0, not clearing the +2 bar needed for conviction.

11. ?Sep 11, 4:20 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    DXCM is down 10.2% from its 30-day high with no clear fundamental impairment visible — no negative earnings revision, no guidance cut, and no company-specific bad news in recent filings or headlines. However, the options flow is notably bearish: P/C ratio of 1.79 with call volume deeply below normal (z=-2.21) and elevated put volume, suggesting informed participants are hedging or positioning for further downside. The sector context is also unfavorable — Health Care ranks 6th of 11 by 30-day relative strength, underperforming SPY by 4.24pts over 30 days, and today's sector flow proxy is heavily negative. Combined with a single insider sale (EVP) on the dip and elevated 10Y yields at 4.83% creating valuation headwinds for growth-oriented med-tech names, the risk/reward is not clearly asymmetric in favor of a large rebound.

12. !Sep 11, 4:20 PMsignalseverity 0.10

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    DXCM is down 10.2% from its 30-day high with no clear fundamental impairment visible — no negative earnings revision, no guidance cut, and no company-specific bad news in recent filings or headlines. However, the options flow is notably bearish: P/C ratio of 1.79 with call volume deeply below normal (z=-2.21) and elevated put volume, suggesting informed participants are hedging or positioning for further downside. The sector context is also unfavorable — Health Care ranks 6th of 11 by 30-day relative strength, underperforming SPY by 4.24pts over 30 days, and today's sector flow proxy is heavily negative. Combined with a single insider sale (EVP) on the dip and elevated 10Y yields at 4.83% creating valuation headwinds for growth-oriented med-tech names, the risk/reward is not clearly asymmetric in favor of a large rebound.

13. ?Sep 11, 3:20 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    DXCM is down 10.2% from its 30-day high with no clear fundamental impairment visible — no negative earnings revision, no guidance cut, and no company-specific bad news in recent filings or headlines. However, the options flow is notably bearish: P/C ratio of 1.79 with call volume deeply below normal (z=-2.21) and elevated put volume, suggesting informed participants are hedging or positioning for further downside. The sector context is also unfavorable — Health Care ranks 6th of 11 by 30-day relative strength, underperforming SPY by 4.24pts over 30 days, and today's sector flow proxy is heavily negative. Combined with a single insider sale (EVP) on the dip and elevated 10Y yields at 4.83% creating valuation headwinds for growth-oriented med-tech names, the risk/reward is not clearly asymmetric in favor of a large rebound.

14. !Sep 11, 3:20 PMsignalseverity 0.10

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    DXCM is down 10.2% from its 30-day high with no clear fundamental impairment visible — no negative earnings revision, no guidance cut, and no company-specific bad news in recent filings or headlines. However, the options flow is notably bearish: P/C ratio of 1.79 with call volume deeply below normal (z=-2.21) and elevated put volume, suggesting informed participants are hedging or positioning for further downside. The sector context is also unfavorable — Health Care ranks 6th of 11 by 30-day relative strength, underperforming SPY by 4.24pts over 30 days, and today's sector flow proxy is heavily negative. Combined with a single insider sale (EVP) on the dip and elevated 10Y yields at 4.83% creating valuation headwinds for growth-oriented med-tech names, the risk/reward is not clearly asymmetric in favor of a large rebound.

15. ?Sep 11, 3:20 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    DXCM is down 10.2% from its 30-day high with no evident fundamental deterioration in recent filings. However, the signal stack is net negative: the options flow shows unusually elevated put volume (P/C ratio 1.79, call z-score of -2.21 indicating below-average call activity), the 10Y yield at 4.83% is a structural headwind for a growth-sensitive medtech name, earnings are 47 days away (a headwind but not a hard veto), the Health Care sector is underperforming SPY meaningfully (-4.24pts over 30 days, which is a mild positive), and there is one insider sale. The broad market tone today is positive but the sector flow proxy is sharply negative (-$7M). Net signal score is approximately -1 to 0, not clearing the +2 bar needed for conviction.

16. !Sep 11, 3:20 PMsignalseverity 0.10

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    DXCM is down 10.2% from its 30-day high with no evident fundamental deterioration in recent filings. However, the signal stack is net negative: the options flow shows unusually elevated put volume (P/C ratio 1.79, call z-score of -2.21 indicating below-average call activity), the 10Y yield at 4.83% is a structural headwind for a growth-sensitive medtech name, earnings are 47 days away (a headwind but not a hard veto), the Health Care sector is underperforming SPY meaningfully (-4.24pts over 30 days, which is a mild positive), and there is one insider sale. The broad market tone today is positive but the sector flow proxy is sharply negative (-$7M). Net signal score is approximately -1 to 0, not clearing the +2 bar needed for conviction.

17. ?Sep 11, 2:21 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    DXCM is down 10.2% from its 30-day high with no clear fundamental impairment visible — no negative earnings revision, no guidance cut, and no company-specific bad news in recent filings or headlines. However, the options flow is notably bearish: P/C ratio of 1.79 with call volume deeply below normal (z=-2.21) and elevated put volume, suggesting informed participants are hedging or positioning for further downside. The sector context is also unfavorable — Health Care ranks 6th of 11 by 30-day relative strength, underperforming SPY by 4.24pts over 30 days, and today's sector flow proxy is heavily negative. Combined with a single insider sale (EVP) on the dip and elevated 10Y yields at 4.83% creating valuation headwinds for growth-oriented med-tech names, the risk/reward is not clearly asymmetric in favor of a large rebound.

18. !Sep 11, 2:21 PMsignalseverity 0.10

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    DXCM is down 10.2% from its 30-day high with no clear fundamental impairment visible — no negative earnings revision, no guidance cut, and no company-specific bad news in recent filings or headlines. However, the options flow is notably bearish: P/C ratio of 1.79 with call volume deeply below normal (z=-2.21) and elevated put volume, suggesting informed participants are hedging or positioning for further downside. The sector context is also unfavorable — Health Care ranks 6th of 11 by 30-day relative strength, underperforming SPY by 4.24pts over 30 days, and today's sector flow proxy is heavily negative. Combined with a single insider sale (EVP) on the dip and elevated 10Y yields at 4.83% creating valuation headwinds for growth-oriented med-tech names, the risk/reward is not clearly asymmetric in favor of a large rebound.

19. ?Sep 11, 2:21 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    DXCM is down 10.2% from its 30-day high with no evident fundamental deterioration in recent filings. However, the signal stack is net negative: the options flow shows unusually elevated put volume (P/C ratio 1.79, call z-score of -2.21 indicating below-average call activity), the 10Y yield at 4.83% is a structural headwind for a growth-sensitive medtech name, earnings are 47 days away (a headwind but not a hard veto), the Health Care sector is underperforming SPY meaningfully (-4.24pts over 30 days, which is a mild positive), and there is one insider sale. The broad market tone today is positive but the sector flow proxy is sharply negative (-$7M). Net signal score is approximately -1 to 0, not clearing the +2 bar needed for conviction.

20. !Sep 11, 2:21 PMsignalseverity 0.10

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    DXCM is down 10.2% from its 30-day high with no evident fundamental deterioration in recent filings. However, the signal stack is net negative: the options flow shows unusually elevated put volume (P/C ratio 1.79, call z-score of -2.21 indicating below-average call activity), the 10Y yield at 4.83% is a structural headwind for a growth-sensitive medtech name, earnings are 47 days away (a headwind but not a hard veto), the Health Care sector is underperforming SPY meaningfully (-4.24pts over 30 days, which is a mild positive), and there is one insider sale. The broad market tone today is positive but the sector flow proxy is sharply negative (-$7M). Net signal score is approximately -1 to 0, not clearing the +2 bar needed for conviction.

21. ❖Sep 10, 4:15 PMnewsvia finnhub

    Dexcom Appoints Glenn Boehnlein to Board of Directors

    SAN DIEGO, September 10, 2026--DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Glenn Boehnlein to its Board of Directors, effective September 10, 2026.

22. ❖Sep 10, 11:21 AMnewsvia finnhub

    3 Quality Compounders with Impressive Fundamentals

    A quality compounder is a business that not only sports durable competitive advantages but also builds on its success by consistently reinvesting its profits at high returns.

23. ❖Sep 9, 7:17 AMnewsvia finnhub

    DexCom, Inc. (DXCM) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

    DexCom, Inc. (DXCM) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 8:00 AM EDTCompany ParticipantsJereme Sylvain - Executive VP, CFO &...

24. ?Sep 8, 12:10 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    DXCM is down 4.03% intraday with no attributable headline, suggesting this is flow-driven selling rather than a news spike that might quickly reverse. The move is meaningful in magnitude and represents real conviction from sellers. However, several factors temper the continuation case: (1) With 215 minutes remaining (~3.5 hours), there is ample time for the move to either continue or mean-revert, which cuts both ways — it doesn't compress the window but also means no urgency to chase. (2) The macro context shows the 5-year forward inflation rate running 1.7σ above trend, which is a headwind for rate-sensitive growth/medical device names like DXCM — this is a mild tailwind for continued downside pressure. (3) No news means no catalyst to anchor a reversal, but also no fresh narrative to sustain momentum. (4) At -4%, DXCM may be approaching intraday oversold conditions that attract mean-reversion buyers, especially in the absence of a fundamental catalyst. Balancing the real selling conviction already in the tape against the lack of a clear continuation catalyst and the elevated macro inflation signal that broadly pressures growth equities, a modest continuation probability is warranted — enough to lean short but without high conviction.

25. !Sep 8, 12:10 PMsignalseverity -0.04

    Agent 7 — Day Trader — day_trade_skipped

    DXCM is down 4.03% intraday with no attributable headline, suggesting this is flow-driven selling rather than a news spike that might quickly reverse. The move is meaningful in magnitude and represents real conviction from sellers. However, several factors temper the continuation case: (1) With 215 minutes remaining (~3.5 hours), there is ample time for the move to either continue or mean-revert, which cuts both ways — it doesn't compress the window but also means no urgency to chase. (2) The macro context shows the 5-year forward inflation rate running 1.7σ above trend, which is a headwind for rate-sensitive growth/medical device names like DXCM — this is a mild tailwind for continued downside pressure. (3) No news means no catalyst to anchor a reversal, but also no fresh narrative to sustain momentum. (4) At -4%, DXCM may be approaching intraday oversold conditions that attract mean-reversion buyers, especially in the absence of a fundamental catalyst. Balancing the real selling conviction already in the tape against the lack of a clear continuation catalyst and the elevated macro inflation signal that broadly pressures growth equities, a modest continuation probability is warranted — enough to lean short but without high conviction.

26. ?Sep 8, 11:10 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    DXCM is down ~3% today with no attributable headline, suggesting either broad sector selling or quiet institutional distribution. With 275 minutes remaining (a full session essentially), there is ample time for the move to extend. The macro context shows 5Y5Y inflation forwards elevated at 1.7σ above trend, which is mildly negative for growth/high-multiple healthcare tech names like DXCM that are rate-sensitive — this provides a weak tailwind for continued selling pressure. No news means no catalyst for a sharp reversal, and the move is large enough to represent real conviction from a seller with size. However, there are meaningful offsets: no volume data to confirm distribution, no sector confirmation, and a 3% move in a volatile name like DXCM can attract dip buyers mid-session especially with so much time left for mean reversion. The setup is marginally in favor of continuation given the macro headwind and absence of a reversal catalyst, but conviction is low. Probability sits just above the threshold — the bounded risk profile (1.5% stop, 3% target) makes the marginal trade worthwhile.

27. !Sep 8, 11:10 AMsignalseverity -0.03

    Agent 7 — Day Trader — day_trade_skipped

    DXCM is down ~3% today with no attributable headline, suggesting either broad sector selling or quiet institutional distribution. With 275 minutes remaining (a full session essentially), there is ample time for the move to extend. The macro context shows 5Y5Y inflation forwards elevated at 1.7σ above trend, which is mildly negative for growth/high-multiple healthcare tech names like DXCM that are rate-sensitive — this provides a weak tailwind for continued selling pressure. No news means no catalyst for a sharp reversal, and the move is large enough to represent real conviction from a seller with size. However, there are meaningful offsets: no volume data to confirm distribution, no sector confirmation, and a 3% move in a volatile name like DXCM can attract dip buyers mid-session especially with so much time left for mean reversion. The setup is marginally in favor of continuation given the macro headwind and absence of a reversal catalyst, but conviction is low. Probability sits just above the threshold — the bounded risk profile (1.5% stop, 3% target) makes the marginal trade worthwhile.

28. ❖Sep 8, 8:36 AMnewsvia finnhub

    DexCom Stock: Is DXCM Underperforming the Healthcare Sector?

    DexCom has underperformed the broader market over the past year, while analysts remain strongly optimistic about its future prospects.

29. ▣Sep 7, 8:00 PMjournalstop

    Agent 2 — Adaptive closed long 114 @ $84.52 (-$315.78)

    Long trailing stop: close $84.52 ≤ trailing floor $85.88 (peak × 0.93)

30. ?Sep 4, 6:02 PMdecisionconsidered

    Agent 1 — Immutable — considered

    Stage 2: close $87.89 > MA150 $72.10 (+21.9%), MA rising, 5.1% off 52w high, vol 0.44× avg

31. ?Sep 4, 10:35 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

32. !Sep 4, 10:35 AMsignalseverity -0.02

    Agent 7 — Day Trader — day_trade_skipped

33. ❖Sep 4, 3:19 AMnewsvia finnhub

    DexCom (DXCM) Stock Looks Undervalued On Fair Value While Earnings Look Fair

    DexCom stock has delivered a mixed ride for long term holders, with the share price down about 35.1% over five years even as a Discounted Cash Flow (DCF) estimate points to an intrinsic value that sits meaningfully above the current market price. At the same time, broader valuation checks lean cautious and market based multiples look roughly in line with peers rather than clearly cheap. Over the past five years, DexCom shareholders have seen the stock decline about 35.1%, which puts more...

34. ?Sep 3, 6:03 PMdecisionconsidered

    Agent 1 — Immutable — considered

    Stage 2: close $89.70 > MA150 $72.00 (+24.6%), MA rising, 3.1% off 52w high, vol 0.23× avg

35. ❖Sep 3, 3:27 PMnewsvia finnhub

    Q2 Earnings Highs And Lows: DexCom (NASDAQ:DXCM) Vs The Rest Of The Patient Monitoring Stocks

    Wrapping up Q2 earnings, we look at the numbers and key takeaways for the patient monitoring stocks, including DexCom (NASDAQ:DXCM) and its peers.

36. ❖Sep 3, 1:51 AMnewsvia finnhub

    Revisiting Stock Picks Dexcom, Bristol Myers Squibb, Quanta Services

    Reviewing prior stock picks is how investors turn experience into valuable feedback. A recommendation is only a thesis until the market tests it. Watch Doug discuss recent stock picks, provide input on the current market environment—and take your questions.

37. ?Sep 2, 6:03 PMdecisionconsidered

    Agent 1 — Immutable — considered

    Stage 2: close $89.69 > MA150 $71.90 (+24.7%), MA rising, 3.1% off 52w high, vol 0.30× avg

38. ?Sep 1, 6:02 PMdecisionconsidered

    Agent 1 — Immutable — considered

    Stage 2: close $90.14 > MA150 $71.79 (+25.6%), MA rising, 2.6% off 52w high, vol 0.78× avg

39. ❖Sep 1, 11:18 AMnewsvia finnhub

    3 Reasons DXCM Has Explosive Upside Potential

    Over the past six months, DexCom has been a great trade, beating the S&P 500 by 11.5%. Its stock price has climbed to $91.17, representing a healthy 23.6% increase. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.

40. ❖Sep 1, 9:30 AMnewsvia finnhub

    Dexcom Announces Upcoming Conference Presentation

    SAN DIEGO, September 01, 2026--DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026.

41. ▣Aug 31, 8:00 PMjournalrotation

    Agent 17 — 52-Week High Momentum closed long 56 @ $91.06 (+$211.12)

    52-Week High monthly rebalance. Position retained in target set; re-entered at equal weight.

42. ?Aug 31, 6:03 PMdecisionconsidered

    Agent 1 — Immutable — considered

    Stage 2: close $91.07 > MA150 $71.68 (+27.0%), MA rising, 1.6% off 52w high, vol 0.86× avg

43. ❖Aug 31, 9:30 AMnewsvia finnhub

    Here's How Much a $1000 Investment in DexCom Made 10 Years Ago Would Be Worth Today

    Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

44. ❖Aug 30, 10:30 AMnewsvia finnhub

    Everything I Learned from My Hot Chart Summer, and How My 21 Stocks Picks Have Performed.

    Great stock picks are just the start to building a portfolio that can shelter you through whatever the market brings.

45. ?Aug 28, 6:02 PMdecisionconsidered

    Agent 1 — Immutable — considered

    Stage 2: close $90.82 > MA150 $71.56 (+26.9%), MA rising, 1.9% off 52w high, vol 0.46× avg

46. ?Aug 27, 6:03 PMdecisionconsidered

    Agent 1 — Immutable — considered

    Stage 2: close $89.30 > MA150 $71.44 (+25.0%), MA rising, 3.6% off 52w high, vol 0.37× avg

47. ❖Aug 27, 7:21 AMnewsvia finnhub

    DexCom (NASDAQ:DXCM): An Affordable Growth Play With Strong Momentum and Fair Valuation

    Discover why DexCom (DXCM) fits the Affordable Growth screen, balancing strong earnings growth with reasonable valuation and solid financial health.

48. ?Aug 26, 6:03 PMdecisionconsidered

    Agent 1 — Immutable — considered

    Stage 2: close $88.96 > MA150 $71.34 (+24.7%), MA rising, 3.9% off 52w high, vol 0.39× avg

49. ❖Aug 26, 5:36 AMnewsvia finnhub

    FDA Approves Abbott's First Wearable Device for Dual Ketone and Glucose Tracking

    The FDA authorized Abbott's Libre Duo 10 Day, the first wearable tracking both glucose and ketones continuously for diabetes patients.

50. ?Aug 25, 6:03 PMdecisionconsidered

    Agent 1 — Immutable — considered

    Stage 2: close $89.16 > MA150 $71.23 (+25.2%), MA rising, 3.7% off 52w high, vol 0.72× avg

51. ❖Aug 24, 7:11 PMnewsvia finnhub

    The Bottom Fishing Club - Embecta: Excellent Turnaround Prospect In Defensive Medical Products

    Embecta (EMBC) looks like a deep value buy: P/E under 3x, 50%+ FCF yield, insider buying and rebound setup.

52. ?Aug 24, 6:03 PMdecisionconsidered

    Agent 1 — Immutable — considered

    Stage 2: close $91.06 > MA150 $71.11 (+28.1%), MA rising, 1.7% off 52w high, vol 0.37× avg

53. ?Aug 11, 10:25 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    DXCM is up 1.65% today with no attributable headline catalyst, suggesting this is either sector rotation or quiet institutional accumulation. The move is below the 2% threshold where momentum becomes self-reinforcing, so conviction is moderate. The macro backdrop shows elevated 5-year forward inflation expectations (T5YIFR at 1.6σ above trend), which is a mild headwind for growth/rate-sensitive names like DXCM — higher real rates pressure high-multiple healthcare tech. However, this macro signal is not acute enough to drive a reversal today. With 320 minutes remaining (over 5 hours), there is ample time for the move to develop further or face a midday fade. No news means no obvious catalyst to fade against, but also no fresh buying catalyst to accelerate. The move is real but modest, macro is a soft headwind, and time is sufficient. Net assessment: slight lean toward continuation given the system's asymmetric payoff structure, but this is a borderline read.

54. !Aug 11, 10:25 AMsignalseverity 0.02

    Agent 7 — Day Trader — day_trade_skipped

    DXCM is up 1.65% today with no attributable headline catalyst, suggesting this is either sector rotation or quiet institutional accumulation. The move is below the 2% threshold where momentum becomes self-reinforcing, so conviction is moderate. The macro backdrop shows elevated 5-year forward inflation expectations (T5YIFR at 1.6σ above trend), which is a mild headwind for growth/rate-sensitive names like DXCM — higher real rates pressure high-multiple healthcare tech. However, this macro signal is not acute enough to drive a reversal today. With 320 minutes remaining (over 5 hours), there is ample time for the move to develop further or face a midday fade. No news means no obvious catalyst to fade against, but also no fresh buying catalyst to accelerate. The move is real but modest, macro is a soft headwind, and time is sufficient. Net assessment: slight lean toward continuation given the system's asymmetric payoff structure, but this is a borderline read.

55. !Aug 10, 6:01 PMsignal

    Agent 1 — Immutable — insufficient_capital

56. ?Aug 7, 6:00 PMdecisionconsidered

    Agent 1 — Immutable — considered

    Stage 2: close $84.74 > MA150 $69.56 (+21.8%), MA rising, 3.5% off 52w high, vol 0.76× avg

57. ?Aug 6, 6:00 PMdecisionconsidered

    Agent 1 — Immutable — considered

    Stage 2: close $82.99 > MA150 $69.44 (+19.5%), MA rising, 5.5% off 52w high, vol 1.19× avg

58. ❖Aug 6, 4:54 PMnewsvia finnhub

    Tracking Baillie Gifford's 13F Portfolio - Q2 2026 Update

    Baillie Gifford Q2 2026 13F: portfolio grew to $110B; SpaceX IPO (SPCX) tops holdings, NVDA added, AMZN trimmed. Read more analysis here.

59. ?Aug 5, 6:01 PMdecisionconsidered

    Agent 1 — Immutable — considered

    Stage 2: close $82.67 > MA150 $69.33 (+19.2%), MA rising, 5.9% off 52w high, vol 0.94× avg

60. ❖Aug 5, 3:05 PMnewsvia finnhub

    Wednesday's session: top gainers and losers in the S&P500 index

    Curious about the S&P500 stocks that are in motion on Wednesday? Join us as we explore the top movers within the S&P500 index during today's session.

61. ?Aug 5, 9:40 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    DXCM is down 2.46% intraday with no attributable headline, suggesting this is technically or flow-driven selling rather than a news catalyst. The move is meaningful but not extreme — it represents real selling pressure but lacks the conviction signal of a major catalyst. Macro context shows T5YIE at 1.9σ below trend (deflation expectations), which is modestly negative for growth/high-multiple names like DXCM (medical devices/diabetes tech carry some rate-sensitivity). With 365 minutes remaining (essentially a full session still ahead), there is ample time for continuation to develop. However, the absence of news cuts both ways — without a clear catalyst, the move could fade as afternoon liquidity returns and dip buyers emerge. No reversal pattern is evident from the data provided. On balance, the path of least resistance remains modestly downward given the established intraday trend, real seller flow, and a macro backdrop that slightly disadvantages growth equities. Assigning a narrow continuation probability just above threshold given the lack of a strong catalyst either way.

62. !Aug 5, 9:40 AMsignalseverity -0.02

    Agent 7 — Day Trader — day_trade_skipped

    DXCM is down 2.46% intraday with no attributable headline, suggesting this is technically or flow-driven selling rather than a news catalyst. The move is meaningful but not extreme — it represents real selling pressure but lacks the conviction signal of a major catalyst. Macro context shows T5YIE at 1.9σ below trend (deflation expectations), which is modestly negative for growth/high-multiple names like DXCM (medical devices/diabetes tech carry some rate-sensitivity). With 365 minutes remaining (essentially a full session still ahead), there is ample time for continuation to develop. However, the absence of news cuts both ways — without a clear catalyst, the move could fade as afternoon liquidity returns and dip buyers emerge. No reversal pattern is evident from the data provided. On balance, the path of least resistance remains modestly downward given the established intraday trend, real seller flow, and a macro backdrop that slightly disadvantages growth equities. Assigning a narrow continuation probability just above threshold given the lack of a strong catalyst either way.

63. ?Aug 4, 6:01 PMdecisionconsidered

    Agent 1 — Immutable — considered

    Stage 2: close $86.93 > MA150 $69.23 (+25.6%), MA rising, 1.0% off 52w high, vol 0.95× avg

64. ❖Aug 4, 7:10 AMnewsvia finnhub

    DexCom (NASDAQ:DXCM) Stands Out as an Affordable Growth Stock

    DexCom earns a 7/10 fundamental rating, blending strong growth, reasonable valuation, and solid profitability as an affordable growth pick.

65. ❖Aug 4, 6:17 AMnewsvia finnhub

    Argus Research Maintains Buy on DexCom, Raises Price Target to $96

    Argus Research analyst Steve Silver maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target from $86 to $96.

66. ❖Aug 3, 8:15 PMnewsvia finnhub

    DexCom (DXCM) Q2 2026 Earnings Call Transcript

    Revenue hit $1.31 billion with strong international growth and margin expansion.

67. !Aug 3, 6:00 PMsignal

    Agent 1 — Immutable — insufficient_capital

68. ✓Aug 3, 6:00 PMdecisionacted

    Agent 2 — Adaptive — entry

    Stage 2: close $87.29 > MA150 $69.10 (+26.3%), MA rising, 0.4% off 52w high, vol 1.52× avg

69. ❖Aug 3, 1:19 PMnewsvia finnhub

    Canaccord Genuity Maintains Buy on DexCom, Raises Price Target to $90

    Canaccord Genuity analyst William Plovanic maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target from $82 to $90.

70. ✓Aug 3, 9:46 AMdecisionacted

    Agent 7 — Day Trader — decide: buy

    DXCM is up ~3.88% today, a meaningful move suggesting real institutional flow, likely driven by earnings sentiment (headline describes a 'cautious buy' post-earnings, implying the stock beat or held expectations). With 360 minutes remaining (session just started or still early), there is ample time for continuation. The macro context (T10Y3M elevated, banking/recession-sensitive sectors reactive) has limited direct bearing on a med-tech/CGM name like DXCM — this is not a rates-sensitive sector in the same way. The 'cautious buy' framing suggests analyst community is supportive but not euphoric, which historically correlates with measured continuation rather than sharp reversal. No clear reversal signal or fade pattern is indicated. The setup is ordinary momentum with a supportive fundamental catalyst — probability sits in the 0.55-0.60 range. No strong reason to fade the move, but not a high-conviction slam-dunk given the 'cautious' tone and lack of explosive volume confirmation data.

71. ❖Aug 3, 9:35 AMnewsvia finnhub

    DexCom (DXCM) Recently Broke Out Above the 20-Day Moving Average

    Is it a good or bad thing when a stock surpasses resistance at the 20-day simple moving average?

72. ❖Aug 3, 9:15 AMnewsvia finnhub

    DexCom, Inc. (DXCM) Hit a 52 Week High, Can the Run Continue?

    DexCom (DXCM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

73. ❖Aug 3, 3:16 AMnewsvia finnhub

    DexCom: Still A Cautious Buy Following Earnings

    Dexcom (DXCM) Q2 earnings beat: G7 adoption, global expansion lift margins and FY26 guidance.

74. ▢Aug 2, 8:00 PMjournal

    Agent 7 — Day Trader opened long 33 @ $86.69

75. ▣Aug 2, 8:00 PMjournaltime_stop

    Agent 7 — Day Trader closed long 33 @ $86.84 (+$4.95)

    EOD forced close — day trader never carries overnight

76. ▢Aug 2, 8:00 PMjournal

    Agent 17 — 52-Week High Momentum opened long 56 @ $87.29

77. ▢Aug 2, 8:00 PMjournal

    Agent 2 — Adaptive opened long 114 @ $87.29

78. ❖Aug 2, 2:10 AMnewsvia finnhub

    DexCom (DXCM) Stock Sees Fair Value Lift After Analyst Target Increases

    DexCom’s fair value estimate has shifted from US$85.24 to US$91.64, marking a moderate uplift in the price target range currently referenced for the stock. This move lines up with recent analyst commentary, where many firms are reaffirming or raising targets, while a smaller group trims expectations on valuation concerns and growth assumptions. As you read on, you will see how these price target adjustments fit into the broader DexCom narrative and what to watch to stay aligned with the...

79. ❖Aug 1, 10:10 AMnewsvia finnhub

    Why DexCom (DXCM) Is Up 16.6% After Raising 2026 Outlook And Expanding Type 2 Access

    In late July 2026, DexCom reported second-quarter results showing higher sales and earnings than a year earlier and raised its full-year 2026 revenue outlook to US$5.18 billion–US$5.25 billion, implying around 11–13% growth. Beyond the headline numbers, DexCom highlighted progress in expanding access for type 2 diabetes patients not using insulin and advancing next-generation sensors, underlining its push into broader metabolic health monitoring. We’ll now look at how DexCom’s raised 2026...

80. ❖Aug 1, 12:19 AMnewsvia finnhub

    DXCM Q2 Deep Dive: Expanded Access and Product Updates Drive Growth

    Medical device company DexCom (NASDAQ:DXCM) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 13.1% year on year to $1.31 billion. The company expects the full year’s revenue to be around $5.22 billion, close to analysts’ estimates. Its non-GAAP profit of $0.70 per share was 15.1% above analysts’ consensus estimates.

81. ✓Jul 31, 6:03 PMdecisionacted

    Agent 20 — SIR Price/Volume — buy

    [cluster_break_up] From 2026-07-06 through 2026-07-30, DXCM traced a tight price cluster spanning roughly $70.48 (Jul 23 low) to $77.98 (Jul 16 spike), with ADV consistently hugging the 20-day mean of ~4.5M — a textbook low-volume consolidation band in 2-D PV space. Today's bar (2026-07-31) ruptures that cluster decisively: close of $83.45 (+11.95%) on 11.8M shares, a volume z-score of 7.09 — more than seven standard deviations above the trailing mean and 2.6× the heaviest prior single day (Jul 16 at 6.6M). In SIR terms, the 2-D path has shot sharply up-and-right in a single session, exiting the cluster on dramatically expanding demand — the defining signature of a cluster_break_up. While single-bar events warrant caution under SIR's path-first doctrine, the magnitude of the volume expansion and the cleanness of the prior consolidation band provide meaningful confirmation that this is fresh, motivated buying rather than noise. Risks: The primary invalidation would be a failure to hold above the cluster ceiling (~$77–$78) on any subsequent pullback, especially if that pullback is accompanied by elevated volume — which would reframe today's bar as an exhaustion/distribution spike rather than a genuine breakout. Additionally, because this is a single-bar event, the absence of confirming follow-through (i.e., at least one or two additional up-day volume dominance sessions in the coming week) would substantially erode conviction and suggest the move was news-driven and unsustainable.

82. ?Jul 31, 6:00 PMdecisionconsidered

    Agent 2 — Adaptive — entry

    [not executed — reserve_floor_or_cash] Stage 2: close $83.45 > MA150 $68.97 (+21.0%), MA rising, 4.1% off 52w high, vol 2.66× avg

83. !Jul 31, 6:00 PMsignal

    Agent 1 — Immutable — insufficient_capital

84. ❖Jul 31, 3:05 PMnewsvia finnhub

    Stay informed with the top movers within the S&P500 index on Friday.

    Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Friday.

85. ❖Jul 31, 1:41 PMnewsvia finnhub

    DexCom Stock Up on Q2 Earnings & Revenue Beat, Margins Rise

    DXCM's Q2 earnings and revenues beat estimates as global demand, broader access and margin expansion fuel stronger 2026 guidance.

86. ❖Jul 31, 12:35 PMnewsvia finnhub

    Friday's session: top gainers and losers in the S&P500 index

    Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Friday.

87. ❖Jul 31, 12:21 PMnewsvia finnhub

    Citigroup Maintains Buy on DexCom, Raises Price Target to $88

    Citigroup analyst Joanne Wuensch maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target from $84 to $88.

88. ❖Jul 31, 11:20 AMnewsvia finnhub

    Dexcom tweaks full-year outlook after reporting 13% growth in Q2

    Following the release of its Q2 results on 30 July, Dexcom's company’s shares on the Nasdaq rose over 8% to $81.04 at market open on 31 July.

89. ❖Jul 31, 10:59 AMnewsvia finnhub

    Why Is DexCom (DXCM) Stock Rocketing Higher Today

    Shares of medical device company DexCom (NASDAQ:DXCM) jumped 10.9% in the morning session after the company reported strong second-quarter results and slightly raised its full-year financial outlook.

90. ❖Jul 31, 10:49 AMnewsvia finnhub

    RBC Capital Maintains Outperform on DexCom, Raises Price Target to $90

    RBC Capital analyst Kendall Au maintains DexCom (NASDAQ:DXCM) with a Outperform and raises the price target from $85 to $90.

91. ❖Jul 31, 10:35 AMnewsvia finnhub

    These S&P500 stocks are gapping in today's session

    Let's have a look at the S&P500 gap up and gap down stocks in today's session.

92. ❖Jul 31, 9:49 AMnewsvia finnhub

    Mizuho Maintains Outperform on DexCom, Raises Price Target to $95

    Mizuho analyst Anthony Petrone maintains DexCom (NASDAQ:DXCM) with a Outperform and raises the price target from $90 to $95.

93. ❖Jul 31, 9:42 AMnewsvia finnhub

    Stock Market Today: Amazon Jumps 15%, Apple Wipes Out $475 Billion

    Amazon surges 15% on an AWS blowout while Apple sheds nearly $475 billion in value. Yields sit at cycle highs.

94. ❖Jul 31, 9:25 AMnewsvia finnhub

    JP Morgan Maintains Neutral on DexCom, Raises Price Target to $82

    JP Morgan analyst Robbie Marcus maintains DexCom (NASDAQ:DXCM) with a Neutral and raises the price target from $65 to $82.

95. ❖Jul 31, 8:35 AMnewsvia finnhub

    Get insights into the top movers in the S&P500 index of Friday's pre-market session.

    Discover the top S&P500 movers in Friday's pre-market session and stay informed about market dynamics.

96. ❖Jul 31, 6:47 AMnewsvia finnhub

    Piper Sandler Reiterates Overweight on DexCom, Raises Price Target to $95

    Piper Sandler analyst Matt O'Brien reiterates DexCom (NASDAQ:DXCM) with a Overweight and raises the price target from $88 to $95.

97. ❖Jul 31, 6:31 AMnewsvia finnhub

    Wells Fargo Maintains Overweight on DexCom, Raises Price Target to $90

    Wells Fargo analyst Larry Biegelsen maintains DexCom (NASDAQ:DXCM) with a Overweight and raises the price target from $85 to $90.

98. ❖Jul 31, 6:05 AMnewsvia finnhub

    AXT Posts Upbeat Q2 Earnings, Joins Newell Brands, SPX Technologies, Amazon And Other Big Stocks Moving Higher On Friday

    U.S. stocks mixed, Nasdaq up 50 pts. AXT Inc (NASDAQ: AXTI) rose 25.3% on strong Q2 results. Other gainers include NWL, FET, IESC, SPXC, AMZN, SPSC, DLB, GH, DXCM, and MPWR.

99. ❖Jul 31, 5:49 AMnewsvia finnhub

    Stifel Maintains Buy on DexCom, Raises Price Target to $95

    Stifel analyst Jonathan Block maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target from $90 to $95.

100. ❖Jul 31, 5:29 AMnewsvia finnhub

     Benchmark Maintains Buy on DexCom, Raises Price Target to $82

     Benchmark analyst Bruce D. Jackson maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target from $77 to $82.

101. ❖Jul 31, 5:10 AMnewsvia finnhub

     Truist Securities Maintains Buy on DexCom, Raises Price Target to $93

     Truist Securities analyst Richard Newitter maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target from $87 to $93.

102. ❖Jul 31, 1:32 AMnewsvia finnhub

     DexCom, Inc. 2026 Q2 - Results - Earnings Call Presentation

     2026-07-31. The following slide deck was published by DexCom, Inc.

103. ❖Jul 31, 1:32 AMnewsvia finnhub

     BTIG Maintains Buy on DexCom, Raises Price Target to $90

     BTIG analyst Marie Thibault maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target from $80 to $90.

104. ❖Jul 31, 1:04 AMnewsvia finnhub

     DexCom Inc (DXCM) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth and Raised Guidance ...

     DexCom Inc (DXCM) delivered 13% revenue growth and raised full-year guidance, driven by strong international performance and improved margins.

105. ❖Jul 30, 9:32 PMnewsvia finnhub

     DexCom (DXCM) Q2 2026 Earnings Call Transcript

     Revenue hit $1.31 billion with strong international growth and margin expansion.

106. ❖Jul 30, 9:17 PMnewsvia finnhub

     DexCom, Inc. Q2 2026 Earnings Call Summary

     Moby summary of DexCom, Inc.'s Q2 2026 earnings call

107. ❖Jul 30, 7:04 PMnewsvia finnhub

     DexCom Q2 Earnings Call Highlights

     DexCom (NASDAQ:DXCM) reported second-quarter 2026 revenue growth of 13% from a year earlier, supported by continued demand for continuous glucose monitoring systems, expanding reimbursement access and share gains across several patient groups and markets. Worldwide revenue totaled $1.31 billion, co

108. ?Jul 23, 6:04 PMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash

     Wanted to buy but only $22.47 cash available; close=$70.47.

109. !Jul 23, 6:04 PMsignal

     Agent 5 — Dip Buyer (Evolving) — insufficient_capital

     DXCM is down 11% from its 30-day high with no identifiable fundamental catalyst (no guidance cut, no going-concern language, no material 8-K disclosures). The Health Care sector is showing relative strength (rank 3/11, outperforming SPY by +4.29pts over 30 days and +1.45pts over 5 days), and today's broad market selloff (SPY -1.24%, QQQ -1.90%) suggests macro/risk-off pressure is the primary driver of the dip rather than a DXCM-specific issue. Options flow is modestly bullish with a P/C ratio of 0.61 and call/put volumes near neutral z-scores, and no imminent earnings event creates a clean 90-day runway.

110. ?Jul 23, 6:04 PMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     DXCM is down 11% from its 30-day high with no identifiable fundamental catalyst — no negative headlines, no earnings imminent, and no guidance cuts visible in the evidence window, suggesting the drop is likely macro/market-driven rather than company-specific deterioration. Health Care sector is showing relative strength (ranked 3/11, +4.29pts vs SPY over 30 days), which is a modest positive for recovery potential, though DXCM dipping while the sector outperforms hints at some idiosyncratic pressure. Options flow is mildly bullish (P/C ratio 0.61, call volume exceeding puts) but both z-scores are near zero, indicating no unusual conviction from smart money.

111. !Jul 23, 6:04 PMsignalseverity 0.11

     Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

     DXCM is down 11% from its 30-day high with no identifiable fundamental catalyst — no negative headlines, no earnings imminent, and no guidance cuts visible in the evidence window, suggesting the drop is likely macro/market-driven rather than company-specific deterioration. Health Care sector is showing relative strength (ranked 3/11, +4.29pts vs SPY over 30 days), which is a modest positive for recovery potential, though DXCM dipping while the sector outperforms hints at some idiosyncratic pressure. Options flow is mildly bullish (P/C ratio 0.61, call volume exceeding puts) but both z-scores are near zero, indicating no unusual conviction from smart money.

112. ?Jul 23, 6:03 PMdecisionconsidered

     Agent 4 — Dip Buyer (Frozen) — decide: skip

     The 11% drawdown from the 30-day high appears largely driven by macro and sector rotation pressures rather than company-specific deterioration — there are no negative news headlines or materially alarming SEC disclosures in the window. DXCM is a high-growth medical device/CGM leader with a strong market position, and the only filing is a routine 8-K with no metrics flagged. However, the flattening yield curve environment (T10Y2Y at 1.8σ below trend) can pressure growth/high-multiple names like DXCM, limiting near-term multiple expansion.

113. !Jul 23, 6:03 PMsignalseverity 0.11

     Agent 4 — Dip Buyer (Frozen) — dip_skipped

     The 11% drawdown from the 30-day high appears largely driven by macro and sector rotation pressures rather than company-specific deterioration — there are no negative news headlines or materially alarming SEC disclosures in the window. DXCM is a high-growth medical device/CGM leader with a strong market position, and the only filing is a routine 8-K with no metrics flagged. However, the flattening yield curve environment (T10Y2Y at 1.8σ below trend) can pressure growth/high-multiple names like DXCM, limiting near-term multiple expansion.

114. ?Jul 22, 2:15 PMdecisionconsidered

     Agent 7 — Day Trader — decide: skip

     DXCM is down 3.77% with 90 minutes remaining — a meaningful move suggesting real institutional selling pressure. No news is available to explain the drop, which is common; the absence of a catalyst doesn't negate the flow signal. The macro context (T10Y2Y 1.7σ below trend, bear-flattening environment) is modestly supportive of risk-off pressure on growth/high-beta names like DXCM, which fits a medical device / CGM growth stock profile. However, with 90 minutes left, there is meaningful time for a mean-reversion bounce, particularly given the lack of a news catalyst — moves without fundamental drivers are more prone to intraday fading as algorithmic and retail buyers step in near key support. The move is also at the boundary of a typical single-day range for this name, suggesting some exhaustion risk. Balancing continuation momentum against fade risk and time-to-close, I assign a modest continuation probability — just enough to trigger the trade given the system's bounded risk parameters.

115. !Jul 22, 2:15 PMsignalseverity -0.04

     Agent 7 — Day Trader — day_trade_skipped

     DXCM is down 3.77% with 90 minutes remaining — a meaningful move suggesting real institutional selling pressure. No news is available to explain the drop, which is common; the absence of a catalyst doesn't negate the flow signal. The macro context (T10Y2Y 1.7σ below trend, bear-flattening environment) is modestly supportive of risk-off pressure on growth/high-beta names like DXCM, which fits a medical device / CGM growth stock profile. However, with 90 minutes left, there is meaningful time for a mean-reversion bounce, particularly given the lack of a news catalyst — moves without fundamental drivers are more prone to intraday fading as algorithmic and retail buyers step in near key support. The move is also at the boundary of a typical single-day range for this name, suggesting some exhaustion risk. Balancing continuation momentum against fade risk and time-to-close, I assign a modest continuation probability — just enough to trigger the trade given the system's bounded risk parameters.

116. ?Jul 22, 9:45 AMdecisionconsidered

     Agent 7 — Day Trader — decide: skip

     DXCM is down ~1.59% intraday, which is a modest but real move. There are no news catalysts to explain the move or suggest further selling pressure, and no catalysts to reverse it either. The macro context (T10Y2Y below trend) is more relevant to banks and defensives than to a medical device/CGM name like DXCM — limited direct bearing. With 360 minutes remaining (essentially a full trading session still ahead), there is ample time for continuation, but the move magnitude is not yet large enough to signal strong directional conviction. No reversal pattern is evident. In the absence of a clear reason to fade and with time remaining, the default lean is slight continuation, but the weak magnitude and lack of supporting evidence keeps this at the floor threshold.

117. !Jul 22, 9:45 AMsignalseverity -0.02

     Agent 7 — Day Trader — day_trade_skipped

     DXCM is down ~1.59% intraday, which is a modest but real move. There are no news catalysts to explain the move or suggest further selling pressure, and no catalysts to reverse it either. The macro context (T10Y2Y below trend) is more relevant to banks and defensives than to a medical device/CGM name like DXCM — limited direct bearing. With 360 minutes remaining (essentially a full trading session still ahead), there is ample time for continuation, but the move magnitude is not yet large enough to signal strong directional conviction. No reversal pattern is evident. In the absence of a clear reason to fade and with time remaining, the default lean is slight continuation, but the weak magnitude and lack of supporting evidence keeps this at the floor threshold.

118. ?Jul 17, 1:35 PMdecisionconsidered

     Agent 7 — Day Trader — decide: skip

     DXCM is down 2.09% with no attributable news catalyst, suggesting the move is likely technical or sector-driven. The macro context shows T10YIE at 1.6σ below trend, indicating lower inflation expectations, which is modestly supportive of long-duration growth names like DXCM — this slightly argues against further downside continuation. With 130 minutes remaining there is ample time for continuation but also for mean reversion. No headlines to anchor a narrative, no clear reversal signal either. The move is meaningful but sits at the lower boundary of the 2-5% conviction range. Absent a clear fade signal or reversal pattern, default lean is slight continuation, but macro tailwind for growth/long-duration names keeps this at the minimum threshold rather than a high-conviction short.

119. !Jul 17, 1:35 PMsignalseverity -0.02

     Agent 7 — Day Trader — day_trade_skipped

     DXCM is down 2.09% with no attributable news catalyst, suggesting the move is likely technical or sector-driven. The macro context shows T10YIE at 1.6σ below trend, indicating lower inflation expectations, which is modestly supportive of long-duration growth names like DXCM — this slightly argues against further downside continuation. With 130 minutes remaining there is ample time for continuation but also for mean reversion. No headlines to anchor a narrative, no clear reversal signal either. The move is meaningful but sits at the lower boundary of the 2-5% conviction range. Absent a clear fade signal or reversal pattern, default lean is slight continuation, but macro tailwind for growth/long-duration names keeps this at the minimum threshold rather than a high-conviction short.

120. ?Jul 17, 10:40 AMdecisionconsidered

     Agent 7 — Day Trader — decide: skip

     DXCM is down 2.10% today with no attributable headline, suggesting either sector rotation, broad risk-off flow, or quiet institutional selling. The macro context shows 10Y inflation expectations (T10YIE) are 1.6σ below trend, which is modestly supportive of growth/long-duration equities like DXCM (a high-multiple MedTech name), creating a mild headwind to further downside continuation. However, a 2.1% move without news represents real selling conviction and the absence of a catalyst means there's no obvious catalyst to reverse it either. With 305 minutes remaining (effectively a full afternoon session), there is ample time for continuation but also for mean reversion. No reversal pattern is evident from the data provided. Balancing the real selling flow against the slightly supportive macro backdrop and no news catalyst to sustain the move, this resolves as a marginal continuation call at the threshold — momentum is the primary driver here.

121. !Jul 17, 10:40 AMsignalseverity -0.02

     Agent 7 — Day Trader — day_trade_skipped

     DXCM is down 2.10% today with no attributable headline, suggesting either sector rotation, broad risk-off flow, or quiet institutional selling. The macro context shows 10Y inflation expectations (T10YIE) are 1.6σ below trend, which is modestly supportive of growth/long-duration equities like DXCM (a high-multiple MedTech name), creating a mild headwind to further downside continuation. However, a 2.1% move without news represents real selling conviction and the absence of a catalyst means there's no obvious catalyst to reverse it either. With 305 minutes remaining (effectively a full afternoon session), there is ample time for continuation but also for mean reversion. No reversal pattern is evident from the data provided. Balancing the real selling flow against the slightly supportive macro backdrop and no news catalyst to sustain the move, this resolves as a marginal continuation call at the threshold — momentum is the primary driver here.

122. ?Jul 16, 9:35 AMdecisionconsidered

     Agent 7 — Day Trader — decide: skip

     DXCM is up 4.76% today with no attributable headline, suggesting institutional or systematic buying rather than retail news chasing. A move of this magnitude on no news implies genuine flow conviction and is not trivially dismissible. However, several factors limit confidence in continuation: (1) With 370 minutes remaining (full trading day essentially ahead), there is ample time for both continuation and mean reversion — large time remaining cuts both ways; (2) The macro context (5Y inflation breakevens 1.6σ below trend) is modestly risk-on for growth/tech-adjacent names like DXCM insofar as lower inflation expectations can support higher-multiple healthcare tech valuations, but the direct sector linkage is weak; (3) No news catalyst means we cannot confirm whether the driver is durable (e.g. fund accumulation) or transient (e.g. options-related delta hedging that could unwind); (4) A 4.76% move already prices in meaningful optimism, raising the probability of profit-taking into the afternoon. On balance, the momentum signal is real and the macro backdrop is not adversarial, supporting a mild continuation bias above 0.5, but the lack of a clear catalyst and the already-extended move cap confidence materially.

123. !Jul 16, 9:35 AMsignalseverity 0.05

     Agent 7 — Day Trader — day_trade_skipped

     DXCM is up 4.76% today with no attributable headline, suggesting institutional or systematic buying rather than retail news chasing. A move of this magnitude on no news implies genuine flow conviction and is not trivially dismissible. However, several factors limit confidence in continuation: (1) With 370 minutes remaining (full trading day essentially ahead), there is ample time for both continuation and mean reversion — large time remaining cuts both ways; (2) The macro context (5Y inflation breakevens 1.6σ below trend) is modestly risk-on for growth/tech-adjacent names like DXCM insofar as lower inflation expectations can support higher-multiple healthcare tech valuations, but the direct sector linkage is weak; (3) No news catalyst means we cannot confirm whether the driver is durable (e.g. fund accumulation) or transient (e.g. options-related delta hedging that could unwind); (4) A 4.76% move already prices in meaningful optimism, raising the probability of profit-taking into the afternoon. On balance, the momentum signal is real and the macro backdrop is not adversarial, supporting a mild continuation bias above 0.5, but the lack of a clear catalyst and the already-extended move cap confidence materially.

124. ?Jul 14, 3:35 PMdecisionconsidered

     Agent 7 — Day Trader — decide: skip

     With only 10 minutes remaining until the forced close, there is extremely limited time for further directional movement even if momentum were intact. The -2.86% move is meaningful and represents real selling pressure, but at this stage of the session the primary risk is mean-reversion or position squaring into close rather than continuation. No news catalyst is present to sustain fresh selling. The macro context (T10Y2Y below trend) is modestly negative for risk assets but DXCM as a med-tech/CGM name is not directly reactive to yield curve signals. With the time horizon effectively collapsed to 10 minutes, the expected move in either direction is minimal, and the asymmetry of catching a late-day fade versus continuation strongly favors passing on this setup. Probability set below 0.5 primarily due to time constraint, not because the prior move lacked conviction.

125. !Jul 14, 3:35 PMsignalseverity -0.03

     Agent 7 — Day Trader — day_trade_skipped

     With only 10 minutes remaining until the forced close, there is extremely limited time for further directional movement even if momentum were intact. The -2.86% move is meaningful and represents real selling pressure, but at this stage of the session the primary risk is mean-reversion or position squaring into close rather than continuation. No news catalyst is present to sustain fresh selling. The macro context (T10Y2Y below trend) is modestly negative for risk assets but DXCM as a med-tech/CGM name is not directly reactive to yield curve signals. With the time horizon effectively collapsed to 10 minutes, the expected move in either direction is minimal, and the asymmetry of catching a late-day fade versus continuation strongly favors passing on this setup. Probability set below 0.5 primarily due to time constraint, not because the prior move lacked conviction.

126. ?Jul 14, 10:05 AMdecisionconsidered

     Agent 7 — Day Trader — decide: skip

     DXCM is down 2.82% today with no identifiable news catalyst, suggesting this is likely flow-driven or sector/market-driven selling. The move is meaningful in magnitude and represents real conviction from someone with size. The macro context (T10Y2Y at 1.9σ below trend, a flattening yield curve) tends to pressure growth/tech-adjacent names like DXCM, which trades more like a high-multiple healthcare tech stock than a defensive. With 340 minutes remaining (roughly equivalent to a mid-morning read), there is ample time for continuation. However, the absence of any news headline makes it harder to assign high conviction — this could be sympathy selling or index rebalancing that fades. No clear reversal pattern is described (no fade off highs back through key levels mentioned). On balance, slight edge to continuation given the magnitude of move, supportive macro headwind for growth names, and sufficient time remaining, but conviction is modest. Probability set just above 0.5 — this is an ordinary momentum read with no strong reason to reverse, but not a high-conviction setup.

127. !Jul 14, 10:05 AMsignalseverity -0.03

     Agent 7 — Day Trader — day_trade_skipped

     DXCM is down 2.82% today with no identifiable news catalyst, suggesting this is likely flow-driven or sector/market-driven selling. The move is meaningful in magnitude and represents real conviction from someone with size. The macro context (T10Y2Y at 1.9σ below trend, a flattening yield curve) tends to pressure growth/tech-adjacent names like DXCM, which trades more like a high-multiple healthcare tech stock than a defensive. With 340 minutes remaining (roughly equivalent to a mid-morning read), there is ample time for continuation. However, the absence of any news headline makes it harder to assign high conviction — this could be sympathy selling or index rebalancing that fades. No clear reversal pattern is described (no fade off highs back through key levels mentioned). On balance, slight edge to continuation given the magnitude of move, supportive macro headwind for growth names, and sufficient time remaining, but conviction is modest. Probability set just above 0.5 — this is an ordinary momentum read with no strong reason to reverse, but not a high-conviction setup.

128. ?Jul 13, 3:25 PMdecisionconsidered

     Agent 7 — Day Trader — decide: skip

     DXCM is up 1.52% today, which is a modest but real move. However, with only 20 minutes remaining until the forced close cutoff, there is very limited time for the move to extend meaningfully toward the +3% profit target. The macro context (T10Y2Y at 2.1σ below trend) is not directly relevant to DXCM as a medical device/CGM company — it is neither a bank nor a defensive sector name, so macro tailwinds/headwinds are neutral to slightly irrelevant. No catalytic news is present. The move size of 1.52% is below the 2-5% threshold that would itself be strong conviction evidence. With 20 minutes left, late-session profit-taking or mean reversion is roughly as likely as continuation, and the asymmetry of time works against reaching the profit target. The setup does not clear the bar for a trade given the time constraint.

129. !Jul 13, 3:25 PMsignalseverity 0.02

     Agent 7 — Day Trader — day_trade_skipped

     DXCM is up 1.52% today, which is a modest but real move. However, with only 20 minutes remaining until the forced close cutoff, there is very limited time for the move to extend meaningfully toward the +3% profit target. The macro context (T10Y2Y at 2.1σ below trend) is not directly relevant to DXCM as a medical device/CGM company — it is neither a bank nor a defensive sector name, so macro tailwinds/headwinds are neutral to slightly irrelevant. No catalytic news is present. The move size of 1.52% is below the 2-5% threshold that would itself be strong conviction evidence. With 20 minutes left, late-session profit-taking or mean reversion is roughly as likely as continuation, and the asymmetry of time works against reaching the profit target. The setup does not clear the bar for a trade given the time constraint.

130. ?Jul 10, 10:20 AMdecisionconsidered

     Agent 7 — Day Trader — decide: skip

     DXCM is up 2.68% intraday with no attributable headline, suggesting organic buying flow or sector rotation rather than a news spike that might fade. The macro context shows 10Y inflation expectations (T10YIE) running 1.5σ below trend at 2.23, which is modestly constructive for long-duration growth names like DXCM (a high-multiple medtech). Lower real rate expectations tend to support valuation multiples in this space. With 325 minutes remaining — essentially a full afternoon session — there is ample time for continuation if the bid holds. No reversal signals are evident from the data provided, and absence of news does not disqualify the momentum. That said, the move is modest in magnitude and lacks a clear catalyst, so this is an ordinary momentum read rather than a high-conviction setup. Probability is set modestly above the 0.5 threshold, reflecting the positive but unremarkable setup.

131. !Jul 10, 10:20 AMsignalseverity 0.03

     Agent 7 — Day Trader — day_trade_skipped

     DXCM is up 2.68% intraday with no attributable headline, suggesting organic buying flow or sector rotation rather than a news spike that might fade. The macro context shows 10Y inflation expectations (T10YIE) running 1.5σ below trend at 2.23, which is modestly constructive for long-duration growth names like DXCM (a high-multiple medtech). Lower real rate expectations tend to support valuation multiples in this space. With 325 minutes remaining — essentially a full afternoon session — there is ample time for continuation if the bid holds. No reversal signals are evident from the data provided, and absence of news does not disqualify the momentum. That said, the move is modest in magnitude and lacks a clear catalyst, so this is an ordinary momentum read rather than a high-conviction setup. Probability is set modestly above the 0.5 threshold, reflecting the positive but unremarkable setup.

132. ?Jul 2, 7:05 AMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash

     Wanted to buy but only $0.31 cash available; close=$68.86.

133. ?Jul 2, 7:05 AMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     DXCM is down 12.5% from its 30-day high with no identifiable fundamental catalyst — no negative news headlines, no insider sales, and no imminent earnings in the visible window. The options flow is modestly bullish (P/C ratio 0.64, call volume exceeding put volume) though neither is at unusual z-scores, suggesting no strong directional conviction from smart money. The healthcare sector has underperformed SPY over the last 5 days (-2.79pts), suggesting this dip is partly sector-driven rather than purely idiosyncratic, which supports mean-reversion potential. Macro conditions are neutral: VIX at 46th percentile and a slightly positive 2s10s spread pose no acute systemic risk.

134. ?Jul 1, 8:12 PMdecisionconsidered

     Agent 4 — Dip Buyer (Frozen) — decide: skip

     DXCM is a leading continuous glucose monitoring company with an established market position and recurring revenue base, suggesting the underlying business remains fundamentally sound. The 12.7% pullback from the 30-day high has no accompanying news headlines or disclosed material events within the window, suggesting the drop may be attributable to broader macro/sector rotation rather than company-specific deterioration. However, the macro backdrop shows inflation expectations (T5YIE) running notably below trend, which could pressure growth-oriented medtech valuations and limit near-term multiple expansion.

135. ?Jun 30, 6:06 PMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash

     Wanted to buy but only $1.25 cash available; close=$67.34.

136. ?Jun 30, 7:04 AMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     DXCM is down 12.5% from its 30-day high with no identifiable fundamental catalyst — no negative news headlines, no insider sales, and no imminent earnings in the visible window. The options flow is modestly bullish (P/C ratio 0.64, call volume exceeding put volume) though neither is at unusual z-scores, suggesting no strong directional conviction from smart money. The healthcare sector has underperformed SPY over the last 5 days (-2.79pts), suggesting this dip is partly sector-driven rather than purely idiosyncratic, which supports mean-reversion potential. Macro conditions are neutral: VIX at 46th percentile and a slightly positive 2s10s spread pose no acute systemic risk.

137. ▣Jun 28, 8:00 PMjournalmanual

     options_momentum closed long 100 @ $2.91 (-$3.38)

     Stop: premium $2.52 ≤ trailing floor $2.59 (peak $3.45 × 0.75)

138. ▢Jun 21, 8:00 PMjournal

     options_momentum opened long 100 @ $2.94

139. ▣Jun 17, 8:00 PMjournalstop

     options_momentum closed long 100 @ $3.07 (-$13.81)

     Stop: premium $3.07 ≤ trailing floor $3.10 (peak $4.13 × 0.75)

140. ▢Jun 15, 8:00 PMjournal

     options_momentum opened long 100 @ $3.21

141. ▣Jun 9, 8:00 PMjournalstop

     options_momentum closed long 100 @ $3.37 (-$113.81)

     Stop: premium $3.37 ≤ trailing floor $3.38 (peak $4.51 × 0.75)

142. ▢Jun 8, 8:00 PMjournal

     options_momentum opened long 100 @ $4.50

143. ▣Jun 4, 8:00 PMjournalmanual

     options_momentum closed long 140 @ $7.31 (+$499.69)

     Stop: premium $6.36 ≤ trailing floor $6.40 (peak $8.54 × 0.75)

144. ▣May 28, 8:00 PMjournaltarget

     options_momentum closed long 60 @ $7.75 (+$240.62)

     De-risk: premium $7.75 ≥ 2.0× entry $3.74. Selling 60/200 contracts; trailing the remainder.

145. ▣May 18, 8:00 PMjournalstop

     options_momentum closed long 400 @ $0.23 (-$952.29)

     Stop: premium $0.23 ≤ trailing floor $1.96 (peak $2.61 × 0.75)

146. ▢May 18, 8:00 PMjournal

     options_momentum opened long 60 @ $3.74

147. ▢May 18, 8:00 PMjournal

     options_momentum opened long 140 @ $3.74

148. ▢May 13, 8:00 PMjournal

     options_momentum opened long 400 @ $2.61